Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted therapy: for kids, too.

Seth J Corey1

  • 1Division of Pediatrics, UT-MD Anderson Cancer Center, Houston, TX 77030, USA. sjcorey@mdanderson.org

Pediatric Blood & Cancer
|February 11, 2005
PubMed
Summary

Signal transduction inhibitor (STI) therapy, or targeted therapy, shows promise for treating pediatric cancers. This approach requires identifying specific molecular targets within tumors for tailored treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tissue-Specific Expression of the EWSR1::FLI1 Fusion Protein Identifies <i>col2a1a</i>-Positive Cells as a Source of Ewing Sarcoma-like Tumors in Zebrafish.

International journal of molecular sciences·2026
Same author

Hog1/p38 and ZAKα drive Shwachman-Diamond syndrome and provide targets to improve cell growth.

bioRxiv : the preprint server for biology·2026
Same author

Oral and Dental Management in Children With Congenital Neutropenia.

Pediatric blood & cancer·2025
Same author

Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series.

Nature communications·2025
Same author

Tafazzin-deficient zebrafish display mitochondrial dysfunction, neutropenia, and metabolic defects without myopathy.

Scientific reports·2025
Same author

Trafficking on the road to neutropenia.

Blood·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapy has historically cured pediatric cancers but was not developed for children.
  • New strategies are needed to improve outcomes in pediatric oncology.
  • Current advancements include gene therapy, immunotherapy, and signal transduction inhibitor (STI) therapy.

Purpose of the Study:

  • To review the critical steps in the pre-clinical development of targeted therapy for pediatric cancers.
  • To highlight the potential of STI therapy in pediatric oncology.
  • To emphasize the need for pediatric oncologists to understand molecular signaling pathways.

Main Methods:

  • Review of pre-clinical development steps for targeted therapy.
  • Discussion of signal transduction pathways as drug targets.
  • Examples from pediatric oncology cases.

Main Results:

  • Signal transduction inhibitor (STI) therapy, also known as targeted therapy, is a promising strategy for pediatric cancers.
  • Successful STI therapy requires identification of relevant molecular targets and development of suitable drugs.
  • Tailoring therapy based on a patient's tumor molecular profile is crucial.

Conclusions:

  • Targeted therapy offers a biologically driven approach to treating pediatric cancers.
  • Pediatric oncologists require enhanced understanding of molecular signaling pathways.
  • Further development of STI therapy is essential for advancing pediatric cancer treatment.

Related Experiment Videos